Literature DB >> 3184763

The clinical course of lung metastases from breast cancer.

O K Schlappack1, M Baur, G Steger, C Dittrich, K Moser.   

Abstract

The clinical course of 50 breast cancer patients whose first metastases were found in the lungs was investigated. 18 months after the start of primary treatment 50% of the patients had developed pulmonary metastases (range: 0-81 months). In 23% of patients a solitary, and in 68% more than one, lung metastases were detected. After a median time of 4 months, in 56% of patients the disease had spread to further organs with bone (25%) and liver (17%) being the most frequent sites. First line management of lung metastases employed surgery, endocrine treatment, chemotherapy or a combination of these modalities. In 24% of patients a complete response was achieved, and in 11% a partial response, with an overall response rate of 35%. Median survival from detection of lung metastases was 13 months (range 4-123+). Patients with only a solitary lung metastasis survived for a median of 11.5 months as compared to 10.5 months for patients with more than one pulmonary metastases. Patients with a disease-free interval of more than 18 months survived significantly longer than patients with a disease-free survival of 18 months or less.

Entities:  

Mesh:

Year:  1988        PMID: 3184763     DOI: 10.1007/bf01726581

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  14 in total

Review 1.  The role of new imaging modalities in staging and follow-up of breast cancer.

Authors:  S A Feig
Journal:  Semin Oncol       Date:  1986-12       Impact factor: 4.929

2.  Survival following local skin recurrence after mastectomy.

Authors:  I S Fentiman; P N Matthews; O W Davison; R R Millis; J L Hayward
Journal:  Br J Surg       Date:  1985-01       Impact factor: 6.939

3.  Association between steroid hormone receptor status and disease-free interval in breast cancer.

Authors:  J C Allegra; M E Lippman; R Simon; E B Thompson; A Barlock; L Green; K K Huff; H M Do; S C Aitken; R Warren
Journal:  Cancer Treat Rep       Date:  1979-08

4.  Clinical course of breast cancer patients with liver metastases.

Authors:  J W Zinser; G N Hortobagyi; A U Buzdar; T L Smith; G Fraschini
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

5.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

6.  Screening for recurrent breast cancer--its effectiveness and prognostic value.

Authors:  R Tomin; W L Donegan
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

7.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

Authors:  K D Swenerton; S S Legha; T Smith; G N Hortobagyi; E A Gehan; H Y Yap; J U Gutterman; G R Blumenschein
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

8.  Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy.

Authors:  V Scheid; A U Buzdar; T L Smith; G N Hortobagyi
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

10.  The clinical course of bone metastases from breast cancer.

Authors:  R E Coleman; R D Rubens
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

View more
  9 in total

Review 1.  Prognostic factors and survival in metastatic breast cancer: A single institution experience.

Authors:  Afef Khanfir; Faiez Lahiani; Racem Bouzguenda; Ines Ayedi; Jamel Daoud; Mounir Frikha
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-14

2.  Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.

Authors:  Sachie Hiratsuka; Shom Goel; Walid S Kamoun; Yoshiro Maru; Dai Fukumura; Dan G Duda; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

3.  Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone.

Authors:  Xin Lu; Yibin Kang
Journal:  J Biol Chem       Date:  2009-08-31       Impact factor: 5.157

Review 4.  Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives.

Authors:  Braeden Medeiros; Alison L Allan
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

Review 5.  Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects.

Authors:  Tabinda Urooj; Bushra Wasim; Shamim Mushtaq; Syed Nudrat Nawaid Shah; Muzna Shah
Journal:  Curr Cancer Drug Targets       Date:  2020       Impact factor: 3.428

6.  Pattern of survival of breast cancer patients in a tertiary hospital in South West Nigeria.

Authors:  Musa Ali-Gombe; Muhammad Inuwa Mustapha; Ayorinde Folasire; Atara Ntekim; Oladapo Babatunde Campbell
Journal:  Ecancermedicalscience       Date:  2021-02-25

7.  Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci.

Authors:  Sachie Hiratsuka; Sachie Ishibashi; Takeshi Tomita; Akira Watanabe; Sachiko Akashi-Takamura; Masato Murakami; Hiroshi Kijima; Kensuke Miyake; Hiroyuki Aburatani; Yoshiro Maru
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.

Authors:  Hyun Sook Lee; Jae In Jung; Kyeong-Hee Kim; Sang Jae Park; Eun Ji Kim
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

Review 9.  Surgical therapy for pulmonary metastasis of breast cancer.

Authors:  Junichi Soh; Yoshifumi Komoike; Tetsuya Mitsudomi
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.